Empagliflozin for treating chronic heart failure with reduced ejection fraction

effective to dapagliflozin and that its costs are identical. It concluded to recommend empagliflozin as an option for treating symptomatic chronic heart failure with reduced ejection fraction. Empagliflozin is not a step-change in treatment but does provide choice for people with heart failure with reduced ejection fraction 3.9 The committee recalled that people with heart failure with reduced ejection fraction have a poor prognosis and that there is an unmet need for treatment options (see section 3.1). It noted that empagliflozin is not the first drug of its class to gain regulatory approval for use in heart failure. So, it could not be considered a step-change in treatment. However, the committee concluded that it could be considered a relevant addition to current treatments and increase clinical choice. Other factors No equalities considerations were identified 3.10 The committee noted that the meta-analysis by Zannad et al. (2020; see section 3.6) suggested that SGLT2 inhibitors were most effective in people with a black or Asian family background. It noted that EMPEROR- Reduced mainly included people with a white family background. The committee noted that neither EMPEROR-Reduced or DAPA-HF was powered to show difference between subgroups of different ages or people from a
